Multihance at 3 Tesla (3T) in Brain Tumors

Last updated: October 14, 2020
Sponsor: Bracco Diagnostics, Inc
Overall Status: Completed

Phase

4

Condition

Memory Loss

Brain Tumor

Astrocytoma

Treatment

N/A

Clinical Study ID

NCT00395863
MH 126
  • Ages > 18
  • All Genders

Study Summary

Compare the efficacy of MultiHance and Magnevist

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Was 18 years or older
  • Provided written informed consent
  • Scheduled for MRI
  • Confirmed or highly suspected to have brain tumor(s) and willing to undergo two MRIexams within 14 days

Exclusion

Exclusion Criteria:

  • Pregnant or lactating females
  • Allergy to one or more of the ingredients in the products or hypersensitivity to anymetals
  • Congestive heart failure, class IV
  • Previous stroke in the past year
  • Received another contrast agent within 24 hours pre and post each exam
  • Investigational product
  • Contraindications to MRI
  • Severe claustrophobia
  • Surgery with 3 weeks prior
  • Steroid therapy or radiosurgery between two exams

Study Design

Total Participants: 46
Study Start date:
November 01, 2006
Estimated Completion Date:
March 31, 2008

Study Description

The purpose of this study was to evaluate whether Multihance is superior to Magnevist in terms of qualitative and quantitative assessment of unenhanced MRI and contrast-enhanced MRI for the visualization of brain disease.

Connect with a study center

  • Bracco Diagnostics, Inc.

    Princeton, New Jersey 08540
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.